Orphan drugs

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Automation / robotics #Business #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #High Content Screening #Molecular medicine #Orphan drugs #RNA #Translational #Translational chemistry

Healthcare and Life Sciences undergoing disruptive change by linked data and semantic technologies

Healthcare and Life Sciences undergoing disruptive change by linked data and semantic technologies By Hans Constandt From early days the sharing of knowledge has been one of the main forces driving science and innovation. Yet latterly, the pharmaceutical industry with its fear of loss of intellectual property has stalled the… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics

Challenges and Opportunities In The Treatment Of Rare Diseases

There are approximately 7,000 rare diseases, which from a regulatory perspective are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Such diseases usually have a genetic basis, often… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Orphan drugs #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

New Tools Increase Accessibility to High Content Screening Assays

New Tools Increase Accessibility to High Content Screening Assays By Dr John Comley There have been major improvements in the instrument offerings and tools that enable high content screening (HCS) over the past decade. In this review we examine the status of high content screening assays today; the motivation to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Orphan drugs #PCR #Pharmacology #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Stem Cells: Cell-Based Assays and the World of Small Molecules

Stem Cells: Cell-Based Assays and the World of Small Molecules By Dr Christina N. Ramirez, Dr Dana C. Duré and Dr Hakim Djaballah Stem cells remain a hot topic in academia and industry alike, and with the potential to cause a paradigm shift where many believe in their ability to… Read More

#Archive

#Analysis #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Pathology #PCR #Protein chemistry / Proteomics #RNA #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Present and Future Challenges in Type 2 Diabetes

By Dr Lesley J Millatt, Dr Rmy Hanf and Dr Dean W Hum According to the International Diabetes Federation, more than 285 million people (6.4% of the world population) are currently estimated to suffer from diabetes, a figure which is expected to rise to 438 million (7.8%) by 2030. Moreover,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Oncology #Orphan drugs #PCR #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

The Post Genomic Era: What Does It All Mean?

The Post Genomic Era: What Does It All Mean? By Dr Chris Torrance Information may no longer be a bottleneck to understanding and tackling complex genetic diseases such as cancer. For those who cut their research teeth not so very long ago, before PCR was thought of by Kary Mullis,… Read More

#Archive

#Business #Clinical specialities #Clinical trials #Drug development #Oncology #Orphan drugs #Regulatory

Making Early Access Real: getting treatments to patients with no other option

Making Early Access Real: getting treatments to patients with no other option By Dr Rav Seeruthun For patients who have no other option to treat their condition, early access to drugs in clinical development can be critical. As a trained physician, there is an intrinsic understanding that early access to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Microbiology #Molecular medicine #Oncology #Orphan drugs #Pathology #PCR #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

High Throughput Flow Cytometry for Discovery at UNMCMD and the NIH Molecular Libraries Initiative

High Throughput Flow Cytometry for Discovery at UNMCMD and the NIH Molecular Libraries Initiative By Dr Larry A. Sklar and Dr Bruce S. Edwards Commercial flow cytometers became widely established in research and clinical laboratories in the 1980s. Once the domain of immunologists and hematologists for cell sorting and analysis,… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biochemistry #Business #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Organic chemistry #Orphan drugs #Preclinical #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Free Online Resources Enabling Crowd-Sourced Drug Discovery

Free Online Resources Enabling Crowd-Sourced Drug Discovery By Dr Antony J. Williams, Valery Tkachenko, Dr Chris Lipinski, Professor Alexander Tropsha and Dr Sean Ekins The availability of freely accessible online resources to enable and support drug discovery has blossomed in recent years. The PubChem platform is now accompanied by a… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Orphan drugs #PCR #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Progress in the Implementation of Label-Free Detection – Cell-based assays

Progress in the Implementation of Label-Free Detection - Cell-based assays By Dr John Comley Progress made in the use of impedance and optical grating technologies for label-free detection of cell-based assays where examined in HTStec's recent Cell-Based Label-Free Detection Trends report. Uniquely all of these label-free offerings are plate-based and… Read More

#Archive

#Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #High Content Screening #Immunology #Lead discovery #Medicinal chemistry #Orphan drugs #Pathology #Pharmacology #Protein chemistry / Proteomics #RNA #Therapeutics #Toxicology

Is Amyloid-related Toxicity an Inevitable Consequence of Ageing?

Is Amyloid-related Toxicity an Inevitable Consequence of Ageing? By Dr J Mark Treherne and Dr David IC Scopes Amyloid-related toxicity need not necessarily be the inevitable consequence of ageing, if some of the new drug discovery strategies to treat neurodegenerative and other ageing-related diseases succeed in the clinic. An increasing… Read More

#Archive

#Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Orphan drugs #PCR #Pharmacology #Regulatory #Screening #Stem cells #System biology #Systems biology

GPCRs – New Strategies for an Old Target Class

William Downey and Dr Shauna Farr-Jones GPCRs are the most studied drug target class and have a proven record as valuable drug targets, with 40-50% of marketed drugs being modulators of GPCR function. Despite the intense effort focused on these targets by the pharmaceutical industry over many years, numerous challenges… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Oncology #Orphan drugs #Pathology #PCR #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Personalised Medicine – Innovation and empowerment or exuberant hyperbole?

Personalised Medicine - Technological innovation and patient empowerment or exuberant hyperbole? By Adam W. Culbertson, Dr Stephen J. Valentine and Dr Stephen Naylor The current paradigm of modern healthcare focuses on patient symptoms, subsequent diagnosis and corresponding treatment of the specific disease(s). Escalating healthcare costs and a trial and error… Read More

#Archive

#Academic #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Orphan drugs #PCR #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Urinary

Emerging concepts of G protein-coupled receptor (GPCR) function and drug discovery

Emerging concepts of G protein-coupled receptor (GPCR) function and drug discovery By Dr Richard M. Eglen, Dr Roger Bosse and Dr Graham S. Long G protein-coupled cell surface receptors (GPCRs) have served a fundamental role in modern pharmacology, due to their central importance in cell communication, and have been the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Flow Cytometry #Genetics #High Content Screening #High throughput screening #Imaging #Lead discovery #Orphan drugs #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Confocal vs Widefield High Content Imaging

Confocal vs Widefield High Content Imaging By Dr John Comley A variety of new confocal hardware and software solutions have recently become available to support high content imaging. Most of the solutions have in common the potential of rejecting out-of-focus background fluorescence and of improving the signal to noise of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Business #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #Lead discovery #Molecular medicine #Organic chemistry #Orphan drugs #Protein chemistry / Proteomics #RNA #System biology #Systems biology #Therapeutics

Whither Pharma? The demise of pharma’s blockbuster business model

By Dr Alpheus Bingham It has been suggested that the blockbuster business model, which has been the key to big pharma success, is now broken and completely beyond repair. In a truly global and fast changing business world, is it time to examine alternatives to the classic monolithic risk structure… Read More

#Archive